Article Dans Une Revue ChemMedChem Année : 2025

β-Glucuronidase-Responsive Albumin-Binding Prodrug of Colchicine-Site Binders for Selective cancer Therapy

Résumé

The development of novel therapeutic strategies enabling the selective destruction of tumors while sparing healthy tissues is of great interest to improve the efficacy of cancer chemotherapy. In this context, we designed a β-glucuronidase-responsive albumin-binding prodrug programmed to release a potent Isocombretastatin A-4 analog within the tumor microenvironment. When injected at a nontoxic dose in mice bearing orthotopic triple-negative mammary tumors, this prodrug produced a significant anticancer activity, therefore offering a valuable alternative to the systemic administration of the parent drug.

Domaines

Fichier principal
Vignette du fichier
ChemMedChem Revised Manuscript clean S Papot 18012025.pdf (1.05 Mo) Télécharger le fichier

Dates et versions

hal-04918349 , version 1 (29-01-2025)

Licence

Identifiants

Citer

Alexandra Bordes, Isabelle Opalinski, Fabien Thoreau, Olivier Provot, Abdallah Hamze, et al.. β-Glucuronidase-Responsive Albumin-Binding Prodrug of Colchicine-Site Binders for Selective cancer Therapy. ChemMedChem, 2025, 20 (9), pp.e202400969. ⟨10.1002/cmdc.202400969⟩. ⟨hal-04918349⟩
86 Consultations
124 Téléchargements

Altmetric

Partager

  • More